Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study
IntroductionPancreatic ductal adenocarcinoma (PDAC) has the highest mortality rate among all solid tumors. Tumorigenesis is promoted by the oncogene KRAS, and KRAS mutations are prevalent in patients with PDAC. Therefore, a comprehensive understanding of the interactions between KRAS mutations and P...
Main Authors: | Fan Yang, Yanjie He, Nan Ge, Jintao Guo, Fei Yang, Siyu Sun |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-01-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1203459/full |
Similar Items
-
Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
by: Prashanth Ashok Kumar, et al.
Published: (2023-06-01) -
Tetrandrine synergizes with MAPK inhibitors in treating KRAS-mutant pancreatic ductal adenocarcinoma via collaboratively modulating the TRAIL-death receptor axis
by: Shuai Tang, et al.
Published: (2023-11-01) -
Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines
by: Yixuan Ma, et al.
Published: (2022-09-01) -
Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
by: Victor Hugo Fonseca de Jesus, et al.
Published: (2023-10-01) -
Ferroptosis: New Strategies and Ideas for the Treatment of Pancreatic Ductal Adenocarcinoma
by: Chengru Yang, et al.
Published: (2024-01-01)